Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph ‐negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation

American Journal of Hematology, EarlyView.
Source: American Journal of Hematology - Category: Hematology Source Type: research

Related Links:

AbstractThe National Institute for Health and Care Excellence (NICE) invited Pfizer, the manufacturer of inotuzumab ozogamicin (henceforth inotuzumab), to submit clinical- and cost-effectiveness evidence for inotuzumab as part of NICE ’s single technology appraisal process. The Centre for Reviews and Dissemination and the Centre for Health Economics, both at the University of York, were commissioned as the independent evidence review group (ERG). The clinical-effectiveness data were from a multicentre randomised controlled tria l that compared inotuzumab with standard of care (SoC), where SoC was the investigator&rsq...
Source: PharmacoEconomics - Category: Health Management Source Type: research
This article reviews the recent advances in the pathophysiology and management of acute lymphoblastic leukemia (ALL) in adults.Recent FindingsAddition of rituximab to standard chemotherapy improves survival in the frontline treatment of B cell ALL, and measurable residual disease (MRD) is the most important prognostic factor. Tyrosine kinase inhibitors (TKI), particularly ponatinib, in combination with Hyper-CVAD significantly improve outcomes in Ph + ALL challenging the benefit of allogeneic stem cell transplant in first line for these patients. Blinatumomab, inotuzumab ozogamicin, and chimeric antigen receptor (CAR) T ce...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
This article reviews the indications of allo-HCT for children and adults diagnosed with ALL, the different sources and conditioning regimens for transplantation as well as the role of measurable residual diseases pre- and post-HCT in the era of the new therapies for ALL. PMID: 30857792 [PubMed - as supplied by publisher]
Source: Medicina Clinica - Category: General Medicine Tags: Med Clin (Barc) Source Type: research
In this study, 5 B-ALL patients who relapsed after allo-HSCT received CAR-DLI (CAR-DLI group), and the outcome was compared with 27 relapsed B-ALL patients who received DLI therapy (DLI group). The median complete remission duration of CAR-DLI group was significantly (P=0.020) longer when compared with DLI group: 9 months (range, 2–29) versus 3.2 months (range, 0–17.4). Furthermore, patients receiving CAR-DLI showed significant (P=0.049) survival advantage over DLI group, with median overall survival of 12 months (range, 3–29) and 3.7 months (range, 0–65), respectively. Of note, no patient developed...
Source: Journal of Immunotherapy - Category: Allergy & Immunology Tags: Clinical Studies Source Type: research
Publication date: Available online 27 February 2019Source: The Lancet HaematologyAuthor(s): Catriona Parker, Shekhar Krishnan, Lina Hamadeh, Julie A E Irving, Roland P Kuiper, Tamas Révész, Peter Hoogerbrugge, Jeremy Hancock, Rosemary Sutton, Anthony V Moorman, Vaskar SahaSummaryBackgroundThe ALLR3 trial investigated outcomes of children with B-cell precursor acute lymphoblastic leukaemia who had late bone marrow relapses. We analysed long-term follow-up outcomes of these patients.MethodsALLR3 was an open-label randomised clinical trial that recruited children aged 1–18 years with B-cell precursor acute...
Source: The Lancet Haematology - Category: Hematology Source Type: research
AbstractPurpose of ReviewThe remarkable improvement in the prognosis of children with acute lymphoblastic leukemia (ALL) has been mainly achieved through the administration of risk-adapted therapy, including allogeneic hematopoietic stem cell transplantation (HSCT). This paper reviews the current indications to HSCT in ALL children, as well as the type of donor and conditioning regimens commonly used. Finally, it will focus on future challenges in immunotherapy.Recent FindingsAs our comprehension of disease-specific risk factors improves, indications to HSCT continue to evolve. Future studies will answer the year-old quest...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
CONCLUSIONS: Despite attempts to reduce cardiotoxicity in childhood cancer treatment, CVD risks in ALL survivors treated more recently do not seem to have declined. PMID: 30852834 [PubMed - in process]
Source: Swiss Medical Weekly - Category: General Medicine Authors: Tags: Swiss Med Wkly Source Type: research
A secondary analysis of data from a phase III trial demonstrated no difference in relapse and inferior survival of patients receiving the lung dose ≥800cGy as part of their TBI regimen. TBI techniques, including the methods of lung dose calculation, were heterogeneous across the institutions participating in this study. These findings led to recommendations of lung-shielding above 800cGy for COG TBI protocols and triggered phantom-based dosim etry investigation of TBI techniques across the institutions.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Clinical Investigation Source Type: research
Conditions:   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   Blasts 5 Percent or More of Peripheral Blood White Cells;   CD22 Positive;   Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells;   Lymphoblasts 20 Percent or More of Peripheral Blood White Cells;   Recurrent B Acute Lymphoblastic Leukemia;   Refractory B Acute Lymphoblastic Leukemia Interventions:   Biological: Inotuzumab Ozogamicin;   Other: Quality-of-Life Asses...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: Patient-related factors, such as age over 9 years and ALL were associated with IGTNs. This is the first report of a survey on IGTNs in patients with hematologic malignancies and solid tumors hospitalized for chemotherapy and stem cell transplantation.
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Online Articles: Original Articles Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Hematology | Leukemia | Stem Cell Therapy | Stem Cells | Transplants